Jiangsu Hengrui Pharmaceuticals (600276.SH): HRS-2129 tablet approved to conduct clinical trials for treating acute pain.
[Translation]
Hengrui Medicine (600276.SH) announced that recently, its subsidiary Shanghai Hengrui Medicine Co., Ltd. and Shandong Shengdi...
Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that its subsidiaries Shanghai Jiangsu Hengrui Pharmaceuticals Co., Ltd. and Shandong Shengdi Pharmaceutical Co., Ltd. have recently received the approval notice for drug clinical trial of HRS-2129 tablets from the National Medical Products Administration ("NMPA"). The approval allows the product to conduct clinical trials for the treatment of acute pain. According to the information available, there are currently no similar products approved for marketing both domestically and internationally.
Related Articles
Through the hearing of the Hong Kong Stock Exchange, Pony.ai (PONY.US) accelerates cross-border capital globalization in the United States and Hong Kong.
Boeing Company (BA.US) has received approval from the FAA to increase the monthly production limit of 737 MAX aircraft to 42.
MRAM, sponsored by Taiwan Semiconductor Manufacturing Co., Ltd. ADR(TSM.US), makes a significant breakthrough.
Through the hearing of the Hong Kong Stock Exchange, Pony.ai (PONY.US) accelerates cross-border capital globalization in the United States and Hong Kong.
Boeing Company (BA.US) has received approval from the FAA to increase the monthly production limit of 737 MAX aircraft to 42.
MRAM, sponsored by Taiwan Semiconductor Manufacturing Co., Ltd. ADR(TSM.US), makes a significant breakthrough.
RECOMMEND
